Ashton Thomas Private Wealth LLC Acquires 10,107 Shares of Gilead Sciences, Inc. $GILD

Ashton Thomas Private Wealth LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 21.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 57,976 shares of the biopharmaceutical company’s stock after buying an additional 10,107 shares during the period. Ashton Thomas Private Wealth LLC’s holdings in Gilead Sciences were worth $6,435,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of GILD. Brighton Jones LLC grew its holdings in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC bought a new stake in Gilead Sciences in the 4th quarter valued at about $215,000. Sivia Capital Partners LLC raised its stake in Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after buying an additional 602 shares during the period. Valeo Financial Advisors LLC boosted its holdings in Gilead Sciences by 26.7% in the second quarter. Valeo Financial Advisors LLC now owns 13,262 shares of the biopharmaceutical company’s stock worth $1,470,000 after acquiring an additional 2,795 shares in the last quarter. Finally, BankPlus Trust Department grew its stake in Gilead Sciences by 333.3% in the second quarter. BankPlus Trust Department now owns 650 shares of the biopharmaceutical company’s stock valued at $72,000 after acquiring an additional 500 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 2.1%

Shares of NASDAQ:GILD opened at $146.23 on Thursday. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $146.73. The company has a market capitalization of $181.42 billion, a PE ratio of 22.67, a price-to-earnings-growth ratio of 0.76 and a beta of 0.36. The business has a fifty day moving average price of $126.41 and a two-hundred day moving average price of $120.40. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on GILD. Rothschild & Co Redburn upped their target price on Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Truist Financial lifted their price objective on shares of Gilead Sciences from $140.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Wolfe Research upped their target price on shares of Gilead Sciences from $150.00 to $155.00 and gave the stock an “outperform” rating in a report on Wednesday, January 28th. Argus lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, TD Cowen increased their price objective on Gilead Sciences from $125.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, January 29th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $136.73.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Wednesday, January 28th. The shares were sold at an average price of $139.89, for a total value of $1,398,900.00. Following the sale, the chief executive officer owned 556,698 shares of the company’s stock, valued at approximately $77,876,483.22. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the transaction, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at $18,709,027.93. This represents a 1.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 257,397 shares of company stock valued at $33,385,512 in the last three months. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.